|
Patent landscape, scope, and claims summary: |
US Patent 8,226,949 (Stability of Monoclonal Antibodies with Alkylglycosides): Claim Scope, Enforceability, and Competitive Patent Landscape
US 8,226,949 claims compositions and methods for stabilizing monoclonal antibodies (mAbs) by formulating with at least one alkylglycoside surfactant. The claims are broad at the concept level (mAb + alkylglycoside to reduce aggregation and/or immunogenicity) but narrow in the actionable claim “hook” (alkylglycosides defined by structural categories, exemplified by C10-C16 maltosides and sucrose monoalkanoates, and with performance thresholds tied to CMC and stability tests). Claim coverage spans liquid and lyophilized formats, multiple administration routes, and includes formulation add-ons (buffers, bulking agents, mucosal enhancers, preservatives, penetration enhancers, epithelial junction modulators, vasodilators, and transport enhancers).
From a freedom-to-operate (FTO) and licensing perspective, enforceability risk concentrates in (i) the selection and concentration regime of alkylglycosides, (ii) whether accused formulations meet the claim’s functional criteria (CMC bands and/or stability/light-scatter and bioactivity retention), and (iii) whether the target antibody falls within the claim’s explicit enumerated antibody list and IgG class language. In generic/biologic competition terms, this patent is not a “biosimilar similarity” patent. It is a formulation-stability patent, meaning the key question is whether competitors use alkylglycoside stabilizers or close equivalents in their commercial products.
What claims does US 8,226,949 cover for monoclonal antibody stability with alkylglycosides?
Core claim concept. Claim 1 is directed to a pharmaceutical composition for increasing stability, reducing aggregation, and/or reducing immunogenicity of a monoclonal antibody comprising:
- the monoclonal antibody; and
- a stabilizing agent comprising at least one alkylglycoside.
Claim 26 is the method mirror: increasing stability by admixing monoclonal antibody, an alkylglycoside stabilizing agent, and a buffering agent.
Claim 1 scope boundaries
- Target molecule: monoclonal antibodies (broad category), with dependent claims narrowing to IgG and further to specific IgG types (claim 3, claim 28).
- Stabilizer: at least one alkylglycoside. This is the principal structural limitation.
- Functional outcomes: stability increase and reduction of aggregation and/or immunogenicity. These are claim recitations that can become dispute points in infringement and validity.
Dependent claim hard points (what narrows coverage)
- Antibody specificity (claim 2): a long list of named mAbs plus adalimumab and others, with multiple generations and formats. The list also includes IgG in the grouping, implying the claims anticipate antibodies and/or antibody subclasses.
- IgG restriction (claim 3): “wherein the monoclonal antibody is IgG.”
- Buffering agent (claim 4): composition further comprising buffering agent (for claim 1, the baseline doesn’t require it; for claim 26 it does).
- Alkylglycoside carbon chain definition (claim 5): alkyl chain 10 to 16 carbons.
- Exemplars (claim 6): dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, and sucrose mono-dodecanoate/mono-tridecanoate/mono-tetradecanoate.
- CMC limitation (claim 7, claim 8):
- claim 7: CMC < 1 mM
- claim 8: CMC < 0.5 mM
- Mucosal delivery enhancers (claim 9-11): includes chitosan and ciliostatic agents as examples.
- Preservatives/additives (claim 12): benzalkonium chloride or chloroethanol.
- Membrane penetration enhancers (claim 13): broad list including surfactants, bile salts, phospholipids, mixed micelles, liposomes, carriers, cyclodextrin derivatives, medium-chain fatty acids, chelators, amino acids/amino-acid salts, nitric oxide donor compounds, etc.
- Route/formulation and physical form (claim 17, claim 25):
- lyophilized (claim 17)
- parenteral, intransal, pulmonary, buccal (claim 25)
- Lyophilized performance (claim 18, claim 23):
- retains >50% biological activity upon reconstitution
- optional bulking agents: albumin, collagen, alginate, mannitol
- Stability readout tied to light scattering (claim 19-21):
- claim 19: stable for ≥1 week under agitation (150 RPM) at 25-37°C by lack of increased light scatter
- claim 20: ≥2 weeks
- claim 21: ≥1 year at ~4°C
- How stability is determined (claim 22): in vivo or in vitro bioactivity assay.
Method claims (claim 26-48) add procedural hooks
Method claims include the same alkylglycoside backbone with additional formulation features and the same performance tests:
- admixing mAb + alkylglycoside + buffering agent (claim 26)
- specific alkylglycoside C10-C16 exemplars (claim 29)
- CMC thresholds (claim 30, claim 31)
- mucosal enhancer options (claim 32-34)
- preservatives (claim 35)
- penetration enhancers (claim 36)
- stability testing via light scattering, including agitation windows and storage (claim 42-44)
- bioactivity retention thresholds for lyophilized reconstitution (claim 41)
- “stability of the composition is determined by light scatter” (claim 48)
Practical enforcement point: if a competitor uses alkylglycosides but does not satisfy the claim’s CMC and/or stability test recitations (or argues that their mechanism is not aggregation/immunogenicity reduction), infringement and damages proofs can become technically and fact-intensive.
How do the alkylglycoside limitations drive infringement risk under US 8,226,949?
The stabilizer is the center of gravity. The claims do not cover “any surfactant.” They require alkylglycosides and tighten with:
- chain length 10 to 16 carbons (claim 5)
- exemplified compounds (claim 6)
- CMC thresholds below 1 mM and 0.5 mM (claim 7-8)
- plus the functional outcome (stability increase, reduced aggregation, reduced immunogenicity).
What counts as an “alkylglycoside” for scope purposes
- Claim 6 uses specific alkylglycosides: maltosides (dodecyl/tridecyl/tetradecyl maltoside) and sucrose monoalkanoates (mono-dodecanoate, etc.).
- Claim 5 indicates the alkyl chain carbon count, suggesting other glycosides with the same chain range can fall within claim scope even if not explicitly listed.
CMC bands: a litigation-grade limitation
CMC is measurable. A competitor can reduce risk by:
- selecting alkylglycosides whose CMC is above the claimed thresholds, or
- using non-alkylglycoside stabilizers,
- or using an alkylglycoside outside the carbon count range,
- or arguing that the “stabilizing agent comprising at least one alkylglycoside” is not present at the claimed effective regime.
Which monoclonal antibodies are explicitly named in US 8,226,949 claim 2 and claim 27?
Dependent claims enumerate a wide set of mAbs. The enumerated list is long and includes (as captured in the claim text provided):
abagovomab, afelimomab, anatumomab mafenatox, arcitumomab, bectumomab, besilesomab, capromab, edobacomab, edrecolomab, elsilimomab, enlimomab, enlimomab pegol, epitumomab cituxetan, ibritumomab tiuxetan, imciromab, inolimomab, mitumomab, oregovmab, satumomab, sulesomab, technetium (99mTc) nofetumomab merpentan, tositumomab, vepalimomab, zolimomab aritox, adalimumab, decatiumumab, belimumab, bertilimumab, denosumab, efungumab, golimumab, ipilimumab, iratumumab, lerdelimumab, lexatumumab, mapatumumab, metelimumab, ofatumumab, panitumumab, pritumumab, raxibacumab, sevirumab, stamulumab, ticilimumab, tuvirumab, votumumab, zalutumumab, zanolimumab, abciximab, basiliximab, bavituximab, cetuximab, ecromeximab, galiximab, infliximab, keliximab, lumiliximab, pagibaximab, priliximab, rituximab, teneliximab, volociximab, alemtuzumab, apolizumab, aselizumab, bapineuzumab, bevacizumab, bivatuzumab, cantuzumab mertansine, certolizumab pegol, daclizumab, eculizumab, efalizurnab, epratuzumab, fontolizumab, gemtuzumab, inotuzumab ozogamicin, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, natalizumab, nimotuzumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pertuzumab, pexelizumab, ranibizumab, reslizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab, tucotuzumab celmoleukin, urtoxazumab, visilizumab, yttrium (90Y) tacatuzumab tetraxetan, and IgG-1 through IgG-4 in the method list.
What that means practically
- If a competitor product uses an alkylglycoside stabilizer in a formulation for one of these named antibodies, dependent claim infringement is more straightforward to plead.
- If the competitor uses a different mAb, claim 1 may still be asserted (because claim 1 is not limited to those named antibodies), but claim-2-type narrowing arguments won’t apply.
When does US 8,226,949 lose exclusivity: what is the likely US patent expiry and how does it interact with biologic exclusivities?
US Patent 8,226,949 is a US nonprovisional filing that issued in the 2012 timeframe (the “8,226,949” series corresponds to that era). Under the standard US rule, utility patent term is 20 years from the earliest effective filing date (subject to PTA and any terminal disclaimer). The patent’s exact expiration date is driven by:
- earliest priority date,
- patent term adjustment (PTA),
- and any terminal disclaimer.
Formulation patents like this also collide with regulatory exclusivity windows differently than new biologic entity (NBE) exclusivity. Even when a formulation patent remains in force, FDA marketing and “biosimilar interchangeability” are not automatically barred unless patents are listed and the biosimilar applicant triggers the Patent List and litigation/dispute provisions.
Because the question asks for timing, exclusivity analysis must integrate:
- patent expiry dates, and
- whether and when the patent is listed in FDA’s Orange Book (for small molecules) or Patent List (for biologics).
No Orange Book / Purple Book / FDA patent listing and no priority/PTA details are provided in the record here. Without the filing dates or listing data for US 8,226,949, an exact calendar expiry and regulatory exclusivity intersection cannot be stated.
What is the Orange Book or Purple Book status of US 8,226,949 and how does listing affect generic or biosimilar entry?
US 8,226,949 concerns monoclonal antibodies (biologics). For biologics, the relevant mechanism is typically the FDA “Patent List” under the BPCI Act rather than the Orange Book (Orange Book is for drugs). Patent listing status drives:
- whether a biosimilar sponsor can file a disclosure,
- whether it must certify for the listed patents,
- and whether a Paragraph IV-type litigation automatically triggers the statutory stay (for biosimilars).
The provided materials include no FDA listing status. Without the specific FDA product(s) to which the patent is tied, no defensible “status” statement can be made.
How strong is the patent estate for alkylglycoside-stabilized monoclonal antibodies: claim breadth vs. vulnerability
Strengths
- Clear technical “center”: alkylglycoside as stabilizer for mAb stability and aggregation reduction.
- Defined chemical space: C10-C16 alkyl chain and specific examples (maltosides and sucrose monoalkanoates).
- Litigation-ready metrics: CMC thresholds and light-scatter stability tests are measurable and can be used for expert-based infringement and non-infringement.
- Route and form coverage: lyophilized and multiple delivery routes broaden commercial coverage.
Vulnerabilities
- Functional breadth can be attacked: “increasing stability, reducing aggregation or reducing immunogenicity” can be argued as result-oriented without sufficient structural limitation, particularly if an accused formulation shows stability improvements for reasons other than reduced aggregation/immunogenicity.
- CMC thresholds are a double-edged sword: they help define scope but also give a clean non-infringement path if a competitor’s CMC is above the cutoffs or if their formulation chemistry differs.
- Antibody enumeration may be argued as limiting in dependent claims: while claim 1 stays broad, dependent claim specificity (claim 2) can create partial defense strategies depending on the accused product’s antibody identity.
- Add-on lists increase complexity: dependent claims 9-16 and 35-39 include broad additive categories (penetration enhancers, transport enhancers). Those terms can create prosecution-history construction fights or novelty challenges depending on prior art.
What prior art likely matters for novelty and obviousness: alkylglycosides, mAb formulation, CMC, and light scattering assays
A formulation patent like this usually faces prior art around:
- use of surfactants and stabilizers for mAb aggregation control,
- alkylglycosides in protein stabilization,
- mAb lyophilization cycles and bulking agents,
- stability assays using light scattering and bioactivity retention,
- and general formulation buffering strategies.
Key novelty levers would include:
- explicit selection of alkylglycosides with C10-C16 chain lengths,
- use of CMC thresholds as claim constraints,
- tying specific stability readouts (light scatter under agitation and storage) to the alkylglycoside formulation system,
- and the particular combination with mAb immunogenicity reduction language.
Given that the claim set includes many broad dependent options, an obviousness attack would argue that it would have been routine to test common stabilizers for mAb aggregation and immunogenicity outcomes. The counter is the specific chemistry (alkylglycoside selection) and quantitated parameters (CMC and performance tests).
How would an accused infringing formulation be evaluated under these claims?
Step 1: Identify alkylglycoside presence
- Is an alkylglycoside used as a stabilizer in the monoclonal antibody formulation?
- Does it fall within the claimed alkyl chain range (C10-C16) and within the claimed exemplar set or equivalent definition?
- Does the formulation include “at least one alkylglycoside” (claim 1, claim 26)?
Step 2: Check CMC
- Does the alkylglycoside in the formulation have a measured CMC below 1 mM (claim 7, claim 30) or below 0.5 mM (claim 8, claim 31)?
- If the competitor uses different glycosides, they can aim to exceed the thresholds or avoid the claimed class.
Step 3: Confirm formulation characteristics
- If asserting lyophilized claim elements: is it lyophilized (claim 17, claim 40)?
- Does reconstitution retain >50% biological activity (claim 18, claim 41)?
- Do stability tests show lack of increased light scatter after specified agitation/storage (claim 19-21, claim 42-44)?
Step 4: Determine antibody identity
- If the assertion relies on dependent claim 2 or method claim 27: is the antibody one of the enumerated mAbs, or at least IgG with the specified IgG subclass (claim 28 for IgG-3)?
Which commercial mAb products are most at risk under US 8,226,949 (product-to-patent mapping)?
No product ingredient lists, labels, or formulation compositions are included in the provided record. Without:
- accused products,
- their formulation excipients (including alkylglycoside identity and chain length),
- and their CMC/stability data,
no defensible “at-risk” product list can be constructed.
How does US 8,226,949 compare with other mAb formulation patents (stability, aggregation inhibition, lyophilization)?
Relative to broader mAb formulation families, this patent is narrower because it:
- requires alkylglycosides as stabilizers,
- restricts to C10-C16 alkyl chains (in dependent claims),
- and adds numeric CMC and assay-based stability limitations.
Compared to patents that cover generic “surfactants” or “stabilizers” broadly, US 8,226,949’s narrower chemistry typically improves invalidity defenses but increases non-infringement opportunities through substitution.
What patent litigation or settlement agreements affect this patent’s practical value?
No litigation docket, PTAB decisions, district court actions, IPR/CBM petitions, or settlement terms are included in the provided record. Without that data, no factual litigation landscape can be reported.
Key Takeaways
- US 8,226,949 is a formulation-stability patent centered on mAbs + alkylglycoside stabilizers, with dependent claim limits keyed to alkyl chain length (C10-C16), specific exemplary alkylglycosides, and CMC thresholds.
- Enforcement risk concentrates on whether an accused mAb product uses alkylglycosides meeting claimed structural and CMC constraints, and whether it satisfies claim performance recitations using light-scatter and/or bioactivity retention measurements.
- The patent broadens commercial relevance through coverage of lyophilized formulations, multiple administration routes, and a wide set of additive options (buffers, bulking agents, mucosal enhancers, preservatives, and penetration/transport enhancers).
- Claim scope is conceptually broad in claim 1, but materially narrowed through chemical definition and quantitative/assay limitations in dependent claims, enabling targeted non-infringement strategies by excipient substitution and formulation parameter changes.
- No defensible exclusivity timeline, Orange Book/Purple Book listing status, or litigation impact can be determined from the information provided.
FAQs
- Do the claims require proof that immunogenicity was actually reduced, or is “stability/aggregation” enough for infringement?
- If a formulation uses an alkylglycoside outside C10-C16, does it avoid all dependent claims even if claim 1 still reads broadly on alkylglycosides?
- Can a competitor avoid the CMC limitations by using the same alkylglycoside but changing the formulation matrix?
- Do lyophilized products face greater infringement exposure because of the >50% biological activity and light-scatter stability windows?
- How does antibody enumeration in dependent claims affect practical infringement analysis for mAbs not listed in claim 2/27?
References
No sources were provided in the input beyond the claim text for US 8,226,949.
More… ↓
⤷ Start Trial
|
